United States-based Resolve Therapeutics has revealed results from its phase two study of RSLV-132 intended for the treatment of primary Sjogren's syndrome (pSS), an autoimmune disease that primarily affects women, it was reported on Wednesday.
The leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489) has published the work.
The phase two study has indicated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the product group, but not the placebo group. The product is a novel, targeted biologic drug aimed at removing pro-inflammatory nucleic acids from the circulation of patients, which is the main reason for multiple pro-inflammatory cascades.
'Up to 75% of pSS patients report profound fatigue as the most debilitating aspect of pSS, so we are pleased that RSLV-132 was able to significantly improve fatigue in this study,' said James Posada, PhD, CEO of Resolve Therapeutics. 'These results represent a potential step forward in the treatment of Sjogren's syndrome, Resolve will confirm the finding in a large Phase 3 study starting in early 2021.'
Grifols Starts Clinical Trial of New Treatment to Provide Immediate Immunity Against COVID-19
Dr. Reddy's Laboratories to begin phase 3 study of Sputnik V vaccine in India
Sirnaomics completes dose administration for first patient in Phase 2a STP705 clinical study
Jubilant Therapeutics collaborates with The Wistar Institute
US FDA approves Janssen Biotech's DARZALEX FASPRO
England opens up its COVID-19 vaccination programme to more groups